CAMP

Healthcare Biotechnology

CAMP4 THERAPEUTICS CORPORATION

$4.00

+0.10 +2.56% today

Price History

Not enough data

Key Stats

Market Cap

251.01M

Avg Volume

258,253

EPS

-$2.32

52W High

$7.75

52W Low

$2.86

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-5.03

P/B Ratio

-307.69

P/S Ratio

59.54

EV/EBITDA

-3.30

EV/Revenue

39.61

Margins

Gross Margin 0.0%

Operating Margin (752.1%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

18.8%

Return on Equity

(545.9%)

Return on Assets

(45.3%)

Liquidity & Leverage

Current Ratio

4.70

Quick Ratio

4.53

Total Cash

86.40M

Total Debt

2.37M

About

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.